Navigation Links
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
Date:5/10/2013

PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies.  Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. 

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, including a potential transaction with Warner Chilcott plc, are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with pending strategic transactions; the difficulty of predicting the timing and outcome of business and corporate development efforts and activities and risks that such activities may not result in a transaction being consummated; the ability to recognize the anticipated synergies and benefits of any transaction; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the period March 31, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )


'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
3. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
4. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
5. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
6. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
9. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
10. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
11. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
(Date:7/13/2017)... 13, 2017  New York City-based market research firm Kalorama ... be aware of.  From new products to new costs, to ... a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment ... of the impact the growing population and, to a more ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... (PRWEB) , ... July 20, ... ... provider of enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, ... world’s largest healthcare services providers. , According to Peter Ohrenberger, sales director ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using ... Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          ... boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device Quality ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
Breaking Medicine News(10 mins):